NCT02275806

Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC

A Phase II Study of Definitive Concurrent Radiation Therapy With Cisplatin and Irinotecan Chemotherapy in Locally Advanced In-operable Non-Small Cell Lung Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Leo W. Jenkins Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single institution phase II study, whose primary objective is to estimate the median and three year survival rate of non-small lung cancer patients with Stage IIIA and IIIB intra-thoracic disease which is referred to as "locally advanced" non-small cell lung cancer (NSCLC).

Detailed description

Patients with histological documented non-small cell lung cancer, that are considered to be inoperable, meet all the eligibility criteria, and sign informed consent will be treated with one cycle of irinotecan and cisplatin, followed by three additional cycles of chemotherapy with 60 - 70 Gy of concurrent radiation therapy.

Conditions

• Lung Neoplasms, Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Irinotecan
DRUG	Cisplatin

Timeline

• Start date: 2014-10-01
• Primary completion: 2017-09-27
• Completion: 2017-09-27
• First posted: 2014-10-27
• Last updated: 2019-08-21

Locations

1 site across 1 country: United States